

Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients with Heart Failure

Circulation: Heart Failure

1, 17-24

DOI: [10.1161/circheartfailure.107.740704](https://doi.org/10.1161/circheartfailure.107.740704)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. <i>Advances in Therapy</i> , 2008, 25, 1288-1302.	2.9	35
2	Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren. <i>Clinical Pharmacokinetics</i> , 2008, 47, 515-531.	3.5	134
3	The Year in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1671-1678.	2.8	5
4	Hyperkalemia Risk and Treatment of Heart Failure. <i>Heart Failure Clinics</i> , 2008, 4, 455-464.	2.1	3
5	Aldosterone Blockade in Patients with Chronic Heart Failure. <i>Cardiology Clinics</i> , 2008, 26, 15-21.	2.2	9
6	Role of renin in heart failure and therapeutic potential of direct renin inhibition. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2008, 9, 177-180.	1.7	13
7	Which strategy in inhibition of the renin-angiotensin system is the most efficient for heart failure?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2008, 9, 184-185.	1.7	0
8	Aliskiren Improves Nitric Oxide Bioavailability and Limits Atherosclerosis. <i>Hypertension</i> , 2008, 52, 467-469.	2.7	8
9	The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 971-981.	2.3	76
10	Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension. <i>Clinical Interventions in Aging</i> , 2009, 4, 137.	2.9	6
11	Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. <i>Vascular Health and Risk Management</i> , 2009, 5, 453.	2.3	28
12	Good News from Aliskiren?. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2862.	0.1	0
13	Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?. <i>Pharmaceuticals</i> , 2009, 2, 118-124.	3.8	3
14	Aliskiren Enhances the Protective Effects of Valsartan Against Cardiovascular and Renal Injury in Endothelial Nitric Oxide Synthase-Deficient Mice. <i>Hypertension</i> , 2009, 54, 633-638.	2.7	60
15	RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice. <i>Heart</i> , 2009, 95, 1205-1208.	2.9	6
16	Dual Blockade of the Renin-Angiotensin-Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. <i>American Journal of Hypertension</i> , 2009, 22, 1032-1040.	2.0	46
17	Managing cardiovascular and renal risk: the potential of direct renin inhibition. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 65-76.	1.7	53
18	Overview of emerging pharmacotherapy in chronic heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2055-2074.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Mineralocorticoid Receptor Blockers and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1685-1691.	4.5	31
20	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology Dialysis Transplantation, 2009, 24, 1663-1671.	0.7	286
21	Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. Future Cardiology, 2009, 5, 453-465.	1.2	5
22	Aliskiren: the next innovation in renin-angiotensin-aldosterone system blockade. Aging Health, 2009, 5, 269-279.	0.3	4
23	Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. Heart, 2009, 95, 1920-1924.	2.9	29
24	The biochemical pharmacology of renin inhibitors: Implications for translational medicine in hypertension, diabetic nephropathy and heart failure: Expectations and reality. Biochemical Pharmacology, 2009, 78, 933-940.	4.4	54
25	Cardiovascular and Renal Surrogate Markers in the Clinical Management of Hypertension. Cardiovascular Drugs and Therapy, 2009, 23, 317-326.	2.6	17
26	Update on renin-angiotensin-aldosterone blockade in heart failure. Current Treatment Options in Cardiovascular Medicine, 2009, 11, 455-466.	0.9	1
27	Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: How much is too much?. Current Heart Failure Reports, 2009, 6, 112-116.	3.3	2
28	Direct renin inhibition: An update. Current Hypertension Reports, 2009, 11, 456-462.	3.5	13
29	Aliskiren and Its Rapidly, Evolving Role in the Management of Cardio-Thoracic Diseases. Heart Lung and Circulation, 2009, 18, 372.	0.4	0
30	ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Current Medical Research and Opinion, 2009, 25, 2287-2301.	1.9	29
31	Recent changes in the landscape of combination RAS blockade. Expert Review of Cardiovascular Therapy, 2009, 7, 1373-1384.	1.5	24
32	Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. Journal of Hypertension, 2009, 27, 2321-2331.	0.5	27
33	Is there a role for direct renin inhibitors in chronic kidney disease?. Current Opinion in Nephrology and Hypertension, 2009, 18, 397-403.	2.0	10
34	Natriuretic Peptide-Guided Management of Acutely Destabilized Heart Failure. Critical Pathways in Cardiology, 2009, 8, 146-150.	0.5	26
36	More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors. Journal of Hypertension, 2010, 28, 1382-1383.	0.5	0
37	How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. Journal of Hypertension, 2010, 28, 1595-1598.	0.5	12

#	ARTICLE	IF	CITATIONS
38	Direct Renin Inhibitors as Antihypertensive Agents. American Journal of Therapeutics, 2010, 17, 237-254.	0.9	13
39	Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. Current Opinion in Nephrology and Hypertension, 2010, 19, 140-152.	2.0	27
40	Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. Journal of Hypertension, 2010, 28, 2145-2155.	0.5	48
41	New Approaches to Blockade of the Renin-Angiotensin-Aldosterone System: Characteristics and Usefulness of the Direct Renin Inhibitor Aliskiren. Journal of Pharmacological Sciences, 2010, 113, 296-300.	2.5	21
42	New Approaches to Blockade of the Renin-Angiotensin-Aldosterone System: Evidence From Randomized Controlled Trials (RCTs) of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Questions Remain Unsolved. Journal of Pharmacological Sciences, 2010, 113, 292-295.	2.5	8
43	New class of agents for treatment of hypertension: Focus on direct renin inhibition. Vascular Health and Risk Management, 2010, 6, 869.	2.3	18
45	The Future of Pharmacological Therapy for Heart Failure. Circulation Journal, 2010, 74, 809-817.	1.6	36
47	Renin Inhibitors in Chronic Heart Failure: The Aliskiren Observation of Heart Failure Treatment Study in Context. Clinical Cardiology, 2010, 33, 536-541.	1.8	13
49	Is There a Place on the Shelf for Aliskiren?. Current Cardiovascular Risk Reports, 2010, 4, 264-270.	2.0	0
50	Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?. Current Cardiology Reports, 2010, 12, 450-463.	2.9	7
51	New Therapeutic Approaches to Resistant Hypertension. Current Hypertension Reports, 2010, 12, 296-302.	3.5	12
52	Role of the Renin-Angiotensin System in Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2010, 24, 341-344.	2.6	25
53	Application of Direct Renin Inhibition to Chronic Kidney Disease. Cardiovascular Drugs and Therapy, 2010, 24, 139-149.	2.6	33
55	Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension. Journal of Clinical Hypertension, 2010, 12, 765-775.	2.0	52
56	Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vascular Health and Risk Management, 2010, 6, 549.	2.3	35
57	First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination. Integrated Blood Pressure Control, 2010, 3, 163.	1.2	4
58	Aliskiren and valsartan combination therapy for the management of hypertension. Vascular Health and Risk Management, 2010, 6, 711.	2.3	14
59	Tratamento da insuficiência cardíaca com fração de ejeção normal. Arquivos Brasileiros De Cardiologia, 2010, 94, 414-426.	0.8	1

#	ARTICLE	IF	CITATIONS
60	Novel neurohormonal insights with therapeutic potential in chronic heart failure. Future Cardiology, 2010, 6, 361-372.	1.2	2
61	Implications of Recently Published Trials of Blood Pressure“Lowering Drugs in Hypertensive or High-Risk Patients. Hypertension, 2010, 55, 819-831.	2.7	44
62	Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?. Future Cardiology, 2010, 6, 129-135.	1.2	4
63	Aliskiren versus ramipril in hypertension. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 193-200.	2.1	23
64	Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 531-548.	4.5	196
66	Is there a future for direct renin inhibitors?. Expert Opinion on Investigational Drugs, 2010, 19, 653-661.	4.1	3
67	The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor?. Hypertension Research, 2010, 33, 4-10.	2.7	40
68	HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure“lessons learnt from a decade of trials. European Journal of Heart Failure, 2010, 12, 99-103.	7.1	5
69	A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. American Journal of Physiology - Renal Physiology, 2010, 299, F929-F941.	2.7	54
70	Aliskiren: A novel, orally active renin inhibitor. Systematic Reviews in Pharmacy (discontinued), 2010, 1, 93.	0.2	5
71	Renin-Angiotensin-Aldosterone System Blockade Effects on the Kidney in the Elderly. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1330-1339.	4.5	51
72	Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. European Heart Journal, 2010, 31, 1993-2005.	2.2	54
73	Blood Pressure and Diabetic Nephropathy. Diabetes Care, 2010, 33, e30-e35.	8.6	7
74	Applications of “decisionable”™ biomarkers in cardiovascular drug development. Biomarkers in Medicine, 2010, 4, 815-827.	1.4	4
75	Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertension Research, 2010, 33, 62-66.	2.7	24
76	Unmet Needs in Managing Hypertension: Potential Role of Direct Renin Inhibition. Postgraduate Medicine, 2010, 122, 203-212.	2.0	7
77	Usefulness of direct renin inhibition with aliskiren as antihypertensive treatment. Hipertension Y Riesgo Vascular, 2010, 27, 245-248.	0.6	2
78	Aliskiren. Drugs, 2010, 70, 2011-2049.	10.9	30

#	ARTICLE	IF	CITATIONS
79	Optimal Antagonism of the Renin-Angiotensin-Aldosterone System. <i>Drugs</i> , 2010, 70, 1215-1230.	10.9	37
80	Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: Antihypertensive effects and benefits beyond BP control. <i>Life Sciences</i> , 2010, 86, 289-299.	4.3	39
81	Elevated Plasma Renin Activity Predicts Adverse Outcome in Chronic Heart Failure, Independently of Pharmacologic Therapy: Data From the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , 2010, 16, 964-970.	1.7	62
83	THE IMPORTANCE OF RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH CARDIO-RENAL DISEASE. <i>Journal of Renal Care</i> , 2010, 36, 97-105.	1.2	3
85	The evolution of angiotensin blockade in the management of cardiovascular disease. <i>Canadian Journal of Cardiology</i> , 2010, 26, 7E-13E.	1.7	10
86	The Effects of Heart Failure on Renal Function. <i>Cardiology Clinics</i> , 2010, 28, 453-465.	2.2	26
87	ARBs and ACEIs together in the treatment of hypertension and its complications? current practical recommendations. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2619-2623.	1.8	3
89	Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 359-373.	2.1	8
90	Aliskiren in the Management of Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 349-358.	2.2	12
91	The Role of Direct Renin Inhibition in Clinical Practice. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 303-315.	2.2	6
92	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011, 13, 755-764.	7.1	19
93	Renin-Angiotensin-Aldosterone Blockade for Cardiovascular Disease Prevention. <i>Cardiology Clinics</i> , 2011, 29, 137-156.	2.2	40
94	Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 115-128.	3.3	10
95	Biomarkers as Surrogate End Points in Heart Failure Trials. <i>Heart Failure Clinics</i> , 2011, 7, 501-507.	2.1	7
96	The Month After. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1967-1969.	2.8	0
99	Chronic Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 153-171.	2.2	65
101	Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations. <i>American Journal of Medicine</i> , 2011, 124, 15-19.	1.5	17
102	p90 ribosomal S6 kinase regulates activity of the renin-angiotensin system: A pathogenic mechanism for ischemia-reperfusion injury. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 51, 272-275.	1.9	6

#	ARTICLE	IF	CITATIONS
103	Aldosterone Antagonists in Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 150-159.	2.0	13
104	Optimal renin-angiotensin-aldosterone system control—direct renin inhibitors beyond blood pressure reductions. Journal of Indian College of Cardiology, 2011, 1, 108-111.	0.1	0
105	Novel therapeutic targets for the treatment of heart failure. Nature Reviews Drug Discovery, 2011, 10, 536-555.	46.4	125
106	Medical therapy for chronic heart failure. Lancet, The, 2011, 378, 713-721.	13.7	73
107	Role of aliskiren in blood pressure control and renoprotection. International Journal of Nephrology and Renovascular Disease, 2011, 4, 41.	1.8	10
108	A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vascular Health and Risk Management, 2011, 7, 297.	2.3	20
109	Potential Benefits of Aliskiren Beyond Blood Pressure Reduction. Cardiology in Review, 2011, 19, 90-94.	1.4	4
110	Safety and Tolerability of the Direct Renin Inhibitor Aliskiren in Combination With Angiotensin Receptor Blockers and Thiazide Diuretics: A Pooled Analysis of Clinical Experience of 12,942 Patients. Journal of Clinical Hypertension, 2011, 13, 506-516.	2.0	23
111	Renin Inhibitors. Journal of Clinical Hypertension, 2011, 13, 662-666.	2.0	9
112	Reducing Cardiorenal Risk Through Combination Therapy With a Direct Renin Inhibitor. Journal of Clinical Hypertension, 2011, 13, 848-855.	2.0	4
113	Treatment of Heart Failure in Long-term Dialysis Patients: A Reappraisal. American Journal of Kidney Diseases, 2011, 57, 760-772.	1.9	14
115	Inhibición directa de la renina y protección de órganos diana. Más allá del descenso de la presión. Revista Española De Cardiología Suplementos, 2011, 11, 18-24.	0.2	0
117	Prognostic Value of Plasma Renin Activity in Heart Failure. American Journal of Cardiology, 2011, 108, 246-251.	1.6	61
118	Rationale for Combining a Direct Renin Inhibitor with other Renin- Angiotensin System Blockers. Focus on Aliskiren and Combinations. Cardiovascular Drugs and Therapy, 2011, 25, 87-97.	2.6	9
119	Effect of Aliskiren in Patients with Heart Failure According to Background Dose of ACE Inhibitor: A Retrospective Analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial. Cardiovascular Drugs and Therapy, 2011, 25, 315-321.	2.6	6
120	Electromechanical effects of the direct renin inhibitor (aliskiren) on the pulmonary vein and atrium. Basic Research in Cardiology, 2011, 106, 979-993.	5.9	24
121	Role of RAAS Inhibition in the Prevention of Cardiovascular Disease. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 279-288.	0.9	6
122	Knocking Out Angiotensin II in the Heart. Current Hypertension Reports, 2011, 13, 129-135.	3.5	12

#	ARTICLE	IF	CITATIONS
123	Less RAAS is more, or not. Expert Review of Cardiovascular Therapy, 2011, 9, 1363-1365.	1.5	2
124	Reducing Cardiovascular Events and End-Organ Damage in Patients with Hypertension: New Considerations. Postgraduate Medicine, 2011, 123, 7-17.	2.0	3
126	Direct Renin Inhibition. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 93-105.	2.2	18
127	Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure, 2011, 13, 100-106.	7.1	68
128	Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. European Journal of Heart Failure, 2011, 13, 107-114.	7.1	113
129	Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure, 2011, 13, 746-754.	7.1	30
130	Attenuation of Brain Damage and Cognitive Impairment by Direct Renin Inhibition in Mice With Chronic Cerebral Hypoperfusion. Hypertension, 2011, 58, 635-642.	2.7	93
131	Direct renin inhibition: update on clinical investigations with aliskiren. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 424-437.	2.8	1
132	Rationale for the use of multiple blockers of the renin-angiotensin-aldosterone system in specific patient populations. Therapy: Open Access in Clinical Medicine, 2011, 8, 227-236.	0.2	3
133	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. European Heart Journal, 2011, 32, 1227-1234.	2.2	130
134	Advances in the Epidemiology of Heart Failure and Left Ventricular Remodeling. Circulation, 2011, 124, e516-9.	1.6	62
135	Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues. Therapeutic Advances in Cardiovascular Disease, 2011, 5, 169-178.	2.1	2
136	Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2011, 4, 569-577.	3.9	219
137	Translational Success Stories: Angiotensin Receptor 1 Antagonists in Heart Failure. Circulation Research, 2011, 109, 437-452.	4.5	56
138	Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study. CardioRenal Medicine, 2011, 1, 53-66.	1.9	9
139	Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. European Heart Journal, 2011, 32, 2135-2142.	2.2	74
140	Effects of Aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertension Research, 2011, 34, 308-313.	2.7	43
141	Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results. Expert Review of Cardiovascular Therapy, 2011, 9, 421-427.	1.5	2

#	ARTICLE	IF	CITATIONS
142	Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. <i>European Heart Journal</i> , 2011, 32, 2642-2649.	2.2	56
143	Limitations of angiotensin inhibition. <i>Nature Reviews Nephrology</i> , 2011, 7, 356-359.	9.6	27
144	Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 409-412.	1.7	22
145	The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2012, 344, e42-e42.	2.3	105
146	Clinical Role of Direct Renin Inhibition in Hypertension. <i>American Journal of Therapeutics</i> , 2012, 19, 204-210.	0.9	12
147	Aliskiren Alone or in Combination for the Treatment of Mild-to-Moderate Hypertension: Current Role and Future Perspectives. <i>Journal of Pharmacy Technology</i> , 2012, 28, 16-25.	1.0	0
148	Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions. <i>Current Drug Safety</i> , 2012, 7, 76-85.	0.6	20
149	Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2012, 14, 341-343.	7.1	737
150	Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice. <i>Hypertension Research</i> , 2012, 35, 62-69.	2.7	19
152	Reversibility of the Effects of Aliskiren in the Renal Versus Systemic Circulation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 258-264.	4.5	11
153	Haemodynamic effects of aliskiren in decompensated severe heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 128-132.	1.7	4
154	How full is our antihypertensives pipeline?. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2012, 3, 7.	0.4	1
155	Comorbid Heart Failure and Renal Impairment: Epidemiology and Management. <i>CardioRenal Medicine</i> , 2012, 2, 281-297.	1.9	18
156	Effects of Aliskiren on Blood Pressure and Myocardial Function Assessed by Global Longitudinal Strain in Patients with Arterial Hypertension and Diastolic Dysfunction. <i>Folia Medica</i> , 2012, 54, 30-34.	0.5	7
157	Editorial [Hot Topic: Current Topics on the Epidemiology, Pathogenesis, and Treatment of Diabetes Mellitus and its Complications (Guest Editors: Moses S. Elisaf and Evangelos C. Rizos)]. <i>Current Vascular Pharmacology</i> , 2012, 10, 138-139.	1.7	0
158	Lipids and Non-Cardiac Vascular Disease: A Lecture Overview. <i>Current Vascular Pharmacology</i> , 2012, 10, 743-744.	1.7	3
159	Combinations of Renin-Angiotensin-Aldosterone System Antagonists: True Advantages?. <i>Current Pharmaceutical Design</i> , 2012, 18, 952-957.	1.9	2
160	Aliskiren Improves Left Ventricular Dysfunction and Reduces Cardiac Dilation in Syrian Cardiomyopathic Hamsters. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 59, 547-552.	1.9	6

#	ARTICLE	IF	CITATIONS
161	Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. Journal of Hypertension, 2012, 30, 107-116.	0.5	27
163	Contemporary Medical Management of Systolic Heart Failure. Circulation Journal, 2012, 76, 268-277.	1.6	24
164	Effect of Direct Renin Inhibitor, Aliskiren, on Peripheral Blood Monocyte Subsets and Myocardial Salvage in Patients With Primary Acute Myocardial Infarction. Circulation Journal, 2012, 76, 1461-1468.	1.6	7
165	Does Direct Inhibition Bring Direct Benefit?. Circulation Journal, 2012, 76, 1326.	1.6	0
166	Novel Treatments for Cardiovascular Disease Prevention. Cardiovascular Therapeutics, 2012, 30, 257-263.	2.5	12
167	Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. New England Journal of Medicine, 2012, 367, 2204-2213.	27.0	1,145
169	Renin activates PI3K&A&E&NOS signalling through the angiotensin AT₁ and Mas receptors to modulate central blood pressure control in the nucleus tractus solitarii. British Journal of Pharmacology, 2012, 166, 2024-2035.	5.4	35
170	Heart Failure in Hypertension. Drugs, 2012, 72, 1373-1398.	10.9	16
171	Inhibition of renin and the (pro)renin receptor system. Blood Pressure, 2012, 21, 377-385.	1.5	1
172	Combined use of direct renin inhibitor and carvedilol in heart failure with preserved systolic function. Medical Hypotheses, 2012, 79, 448-451.	1.5	1
173	The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and&E& beyond. Expert Review of Cardiovascular Therapy, 2012, 10, 713-725.	1.5	10
175	Managing the Kidney when the Heart is Failing. , 2012, , .		0
176	Editorial: [Aliskiren/Amlodipine Single-Pill Combinations: More Evidence in Favour of Combination Formulations for the Treatment of Hypertension]. Current Vascular Pharmacology, 2012, 10, 745-747.	1.7	1
177	Mensagem do Editor. Arquivos Brasileiros De Cardiologia, 2012, 99, 575-575.	0.8	32
178	Aliskiren suppresses the renin–angiotensin–aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension. International Journal of Nephrology and Renovascular Disease, 2012, 5, 125.	1.8	2
179	Cardiomyocyte and Heart Failure. , 2012, , .		1
180	Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2012, 26, 131-143.	2.6	10
181	New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Failure Reviews, 2012, 17, 191-201.	3.9	64

#	ARTICLE	IF	CITATIONS
182	The Neurohormonal Network in the RAAS Can Bend Before Breaking. <i>Current Heart Failure Reports</i> , 2012, 9, 81-91.	3.3	9
183	Aliskiren-associated acute kidney injury in a patient with pre-existing chronic kidney disease and dilated cardiomyopathy. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 333-336.	1.6	7
184	Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry. <i>International Journal of Clinical Practice</i> , 2012, 66, 251-261.	1.7	13
185	How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?. <i>Cellular Signalling</i> , 2012, 24, 1583-1591.	3.6	13
186	Combined Blockade of the Renin System: An Example of Hormesis. <i>Journal of Clinical Hypertension</i> , 2012, 14, 573-574.	2.0	0
187	Novel therapies in acute and chronic heart failure. , 2012, 135, 1-17.		45
188	Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 470-481.	2.4	5
189	Review of Vasodilators in Acute Decompensated Heart Failure: The Old and the New. <i>Journal of Cardiac Failure</i> , 2013, 19, 478-493.	1.7	28
190	Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?. <i>Cardiovascular Diabetology</i> , 2013, 12, 108.	6.8	9
191	Novel Pharmacologic Therapies in Development for Acute Decompensated Heart Failure. <i>Current Cardiology Reports</i> , 2013, 15, 329.	2.9	4
192	Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. <i>Heart and Vessels</i> , 2013, 28, 442-452.	1.2	7
193	Almanac 2013: heart failure. <i>Heart</i> , 2013, 99, 1562-1566.	2.9	4
194	Pathological Ventricular Remodeling. <i>Circulation</i> , 2013, 128, 1021-1030.	1.6	126
195	Fast, simultaneous quantification of three novel cardiac drugs in human urine by MEPSâ€UHPLCâ€MS/MS for therapeutic drug monitoring. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 938, 86-95.	2.3	33
196	The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1041-1047.	4.1	23
197	When Conventional Heart Failure Therapy is Not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist?. <i>Congestive Heart Failure</i> , 2013, 19, 107-115.	2.0	25
198	The past, present and future of reninâ€angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	1.7	97
199	Combination Angiotensin Converting Enzyme and Direct Renin Inhibition in Heart Failure following Experimental Myocardial Infarction. <i>Cardiovascular Therapeutics</i> , 2013, 31, 84-91.	2.5	12

#	ARTICLE	IF	CITATIONS
200	Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA-salt-induced hypertension in rats. <i>Molecular and Cellular Biochemistry</i> , 2013, 373, 189-194.	3.1	36
201	Targeting the renin-angiotensin-aldosterone system in heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 125-134.	13.7	78
202	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1125.	7.4	297
203	An evaluation of the latest evidence relating to renin-angiotensin system inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 847-858.	3.3	6
204	Aliskiren inhibits experimental venous thrombosis in two-kidney one-clip hypertensive rats. <i>Thrombosis Research</i> , 2013, 131, e39-e44.	1.7	4
205	It is Time to Reconsider the Cardiovascular Protection Afforded by RAAS Blockade - Overview of RAAS Systems. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 133-138.	2.6	8
206	Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 145-153.	2.6	24
207	Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2013, 15, 1205-1207.	7.1	5
208	Pharmacological management of chronic heart failure: old drugs, new drugs and new indications. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, C18-C22.	0.5	2
209	Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. <i>BMJ, The</i> , 2013, 346, f360-f360.	6.0	185
210	Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 232-241.	2.5	30
211	Pharmacologic Management of Heart Failure in the Ambulatory Setting. , 2013, , 241-269.		1
212	Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. <i>Hepatology Research</i> , 2013, 43, 1241-1250.	3.4	25
213	Effects of Direct Renin Inhibition on Atherosclerotic Biomarkers in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 427-432.	2.0	3
214	Direct renin inhibition: extricating facts from fables. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013, 7, 153-167.	2.1	3
215	Angiotensin II and Oxidative Stress in the Failing Heart. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 1095-1109.	5.4	93
216	Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis. <i>Hypertension Research</i> , 2013, 36, 252-261.	2.7	25
217	Review of direct renin inhibition by aliskiren. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013, 14, 193-196.	1.7	19

#	ARTICLE	IF	CITATIONS
218	Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). Circulation Journal, 2013, 77, 231-248.	1.6	82
219	Hipertens�o arterial sist�mica prim�ria. Medicina, 2013, 46, 256-272.	0.1	5
220	Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. BioMed Research International, 2014, 2014, 1-21.	1.9	107
222	Effect of Direct Renin Inhibitor on Left Ventricular Remodeling in Patients With Primary Acute Myocardial Infarction. International Heart Journal, 2014, 55, 17-21.	1.0	5
223	Current treatments for acute heart failure: focus on serelaxin. Research Reports in Clinical Cardiology, 2014, , 169.	0.2	1
224	Almanac 2013: heart failure. Anatolian Journal of Cardiology, 2014, 14, 313-318.	0.4	0
225	Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists. Clinical and Experimental Hypertension, 2014, 36, 497-502.	1.3	5
226	Heart failure highlights in 2012��2013. European Journal of Heart Failure, 2014, 16, 122-132.	7.1	11
227	Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin��Angiotensin��Aldosterone System Antagonists. American Journal of Therapeutics, 2014, 21, 419-435.	0.9	8
228	Direct Renin Inhibitor Induced Renal Failure. American Journal of Therapeutics, 2014, 21, e53-e55.	0.9	3
229	Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. Clinical and Experimental Nephrology, 2014, 18, 821-830.	1.6	6
230	Natriuretic peptide-guided heart failure management. European Heart Journal, 2014, 35, 16-24.	2.2	159
231	Antihypertensive effect of caffeic acid and its analogs through dual renin��angiotensin��aldosterone system inhibition. European Journal of Pharmacology, 2014, 730, 125-132.	3.5	69
232	The Renin-Angiotensin-Aldosterone System and Heart Failure. Cardiology Clinics, 2014, 32, 21-32.	2.2	139
233	Novel drug targets in clinical development for heart failure. European Journal of Clinical Pharmacology, 2014, 70, 765-774.	1.9	22
234	Renin��Angiotensin System Blocking Drugs. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 14-33.	2.0	53
235	State of the art paper Aliskiren �� an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension. Archives of Medical Science, 2014, 4, 830-836.	0.9	6
236	Esc. Acta Cardiologica, 2014, 69, 341-347.	0.9	0

#	ARTICLE	IF	CITATIONS
238	Effect of aliskiren on vascular remodelling in small retinal circulation. Journal of Hypertension, 2015, 33, 2491-2499.	0.5	13
239	A Direct Renin Inhibitor Aliskiren: Re-Evaluation of Effectiveness. Journal of Drug Metabolism & Toxicology, 2015, 06, .	0.1	0
240	Fluid Management In Patients With Chronic Heart Failure. Cardiac Failure Review, 2015, 1, 90.	3.0	56
241	Can Aliskiren be Considered as a New Novel Drug for Hypertension?. Cureus, 2015, 7, e375.	0.5	1
242	Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 126-131.	3.0	13
243	Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and) Tj ETQq1 1 0.784314,rgBT /Overlock 10 Heart Journal, 2015, 169, 693-701.e3.	2.7	16
244	Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases. , 2015, , 751-806.		2
245	Effects Of The Direct Renin Inhibitor Aliskiren On Oxidative Stress In Isolated Rat Heart. Serbian Journal of Experimental and Clinical Research, 2015, 16, 193-199.	0.1	0
246	Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E435-E449.	3.5	91
247	Contemporary Drug Development in Heart Failure. Circulation: Heart Failure, 2015, 8, 826-831.	3.9	34
248	Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 956-964.	1.7	9
249	Combination therapy in chronic kidney disease?. Therapeutic Advances in Cardiovascular Disease, 2015, 9, 147-152.	2.1	3
250	Role of the Renin-Angiotensin-Aldosterone System in the Management of Neonatal Heart Failure. NeoReviews, 2015, 16, e575-e585.	0.8	2
251	New medical therapies for heart failure. Nature Reviews Cardiology, 2015, 12, 730-740.	13.7	43
252	Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. Clinica Chimica Acta, 2015, 443, 85-93.	1.1	22
253	Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls. Current Hypertension Reports, 2015, 17, 511.	3.5	5
256	Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. Therapeutics and Clinical Risk Management, 2016, 12, 887.	2.0	16
257	The bumpy road to drug development for acute heart failure. European Heart Journal Supplements, 2016, 18, G19-G32.	0.1	24

#	ARTICLE	IF	CITATIONS
258	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2016, 374, 1521-1532.	27.0	204
259	Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure. <i>Kidney Research and Clinical Practice</i> , 2016, 35, 219-228.	2.2	13
260	Differing Effects of Aliskiren/Amlodipine Combination and High-Dose Amlodipine Monotherapy on Ambulatory Blood Pressure and Target Organ Protection. <i>Journal of Clinical Hypertension</i> , 2016, 18, 70-78.	2.0	9
261	Direct Renin Inhibitor is Better than Angiotensin II Receptor Blocker for Intrarenal Arterioles. <i>Kidney and Blood Pressure Research</i> , 2016, 41, 561-569.	2.0	5
262	The Future of Clinical Trials in Cardiovascular Medicine. <i>Circulation</i> , 2016, 133, 2662-2670.	1.6	33
263	New Targets in the Drug Treatment of Heart Failure. <i>Drugs</i> , 2016, 76, 187-201.	10.9	2
264	New Management Strategies in Heart Failure. <i>Circulation Research</i> , 2016, 118, 480-495.	4.5	37
265	Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis. <i>International Journal of Cardiology</i> , 2016, 205, 65-71.	1.7	23
266	Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	89
267	Successful long-term effects of direct renin inhibitor aliskiren in a patient with atherosclerotic renovascular hypertension. <i>CEN Case Reports</i> , 2017, 6, 66-73.	0.9	3
268	Aliskiren Improves Ischemia- and Oxygen Glucose Deprivation-Induced Cardiac Injury through Activation of Autophagy and AMP-Activated Protein Kinase. <i>Frontiers in Pharmacology</i> , 2017, 8, 819.	3.5	11
269	Renin Inhibition with Aliskiren: A Decade of Clinical Experience. <i>Journal of Clinical Medicine</i> , 2017, 6, 61.	2.4	20
270	Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis. <i>Oncotarget</i> , 2017, 8, 89364-89374.	1.8	9
271	Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level. <i>Hypertension Research</i> , 2018, 41, 435-443.	2.7	9
272	Renin-angiotensin system inhibition—it's been a long but fruitful journey. <i>European Journal of Heart Failure</i> , 2018, 20, 687-688.	7.1	0
273	Combination Therapy of Renin Angiotensin System Inhibitors and Î²-Blockers in Patients with Heart Failure. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1067, 17-30.	1.6	7
274	Newer hormonal pharmacotherapies for heart failure. <i>Expert Review of Endocrinology and Metabolism</i> , 2018, 13, 35-49.	2.4	1
275	Low- and High-renin Heart Failure Phenotypes with Clinical Implications. <i>Clinical Chemistry</i> , 2018, 64, 597-608.	3.2	52

#	ARTICLE	IF	CITATIONS
276	Myocardial Cell Signaling During the Transition to Heart Failure. , 2018, 9, 75-125.		12
277	OBSOLETE: Neurohormonal Blockade. , 2018, , .		0
278	PHARMACOTHERAPY OF HEART FAILURE. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 78.	0.3	2
279	Neurohormonal Blockade. , 2018, , 459-476.		0
280	TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model. PLoS ONE, 2018, 13, e0202176.	2.5	6
281	The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial. American Heart Journal, 2018, 201, 164-167.	2.7	5
282	Renin Activity in Heart Failure with Reduced Systolic Functionâ€”New Insights. International Journal of Molecular Sciences, 2019, 20, 3182.	4.1	31
283	Evaluation of preclinical safety profile of SPH3127, a direct renin inhibitor, after 28-day repeated oral administration in Sprague-Dawley rats and cynomolgus monkeys. Regulatory Toxicology and Pharmacology, 2019, 109, 104484.	2.7	2
284	The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis. Journal of Human Hypertension, 2019, 33, 795-806.	2.2	3
285	Relation between therapyâ€”induced changes in natriuretic peptide levels and longâ€”term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2019, 21, 613-620.	7.1	9
286	Pharmacotherapy in Heart Failure (I): Renin-Angiotensin-Aldosterone System (incl. ARNI), Diuretics, Digoxin and Statins. Cardiovascular Medicine, 2019, , 105-120.	0.0	0
288	Effects of dual blockade in heart failure and renal dysfunction: Systematic review and meta-analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2019, 20, 147032031988265.	1.7	2
289	Efficacy of aliskiren supplementation for heart failure. Herz, 2019, 44, 398-404.	1.1	3
290	The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Failure Reviews, 2020, 25, 31-42.	3.9	52
291	Significance of the Renin-Angiotensin System in Clinical Conditions. , 0, , .		6
292	<scp>VICTORIA</scp> in context. European Journal of Heart Failure, 2020, 22, 1747-1751.	7.1	2
293	Pharmacological interventions for heart failure in people with chronic kidney disease. The Cochrane Library, 2020, 2020, CD012466.	2.8	7
294	Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules. Bioorganic and Medicinal Chemistry, 2020, 28, 115466.	3.0	13

#	ARTICLE	IF	CITATIONS
295	Efficacy of Add-on Therapy with Carvedilol and the Direct Renin Inhibitor Aliskiren for Improving Cardiac Sympathetic Nerve Activity, Cardiac Function, Symptoms, Exercise Capacity and Brain Natriuretic Peptide in Patients with Dilated Cardiomyopathy. <i>Annals of Nuclear Cardiology</i> , 2021, 7, 33-42.	0.2	0
296	Aging and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy. , 2014, , 259-289.		6
297	AT1 Receptors, Angiotensin Receptor Blockade, and Clinical Hypertensive Disease. , 2009, , 59-79.		2
298	Aliskiren for heart failure: a systematic review and meta-analysis of randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 88189-88198.	1.8	5
299	Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 459.	2.0	15
300	Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition. <i>Reviews on Recent Clinical Trials</i> , 2011, 6, 134-146.	0.8	32
301	Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2020, 2, 113.	0.1	12
302	Aliskiren, the first direct renin inhibitor for treatment of hypertension. <i>Journal of Postgraduate Medicine</i> , 2012, 58, 32-38.	0.4	7
303	The Renin-Angiotensin-Aldosterone System in Renal and Cardiovascular Disease and the Effects of its Pharmacological Blockade. <i>Journal of Diabetes & Metabolism</i> , 2012, 03, .	0.2	13
304	Renin and cardiovascular disease: Worn-out path, or new direction. <i>World Journal of Cardiology</i> , 2011, 3, 72.	1.5	9
305	Assessing the benefits of natriuretic peptides-guided therapy in chronic heart failure. <i>Cardiology Journal</i> , 2015, 22, 5-11.	1.2	9
306	Pharmacologic Management of Heart Failure in the Ambulatory Setting. , 2007, , 331-362.		0
307	Inhibiting the Renin Angiotensin Aldosterone System in Patients with Heart Failure and Myocardial Infarction. , 2009, , 93-102.		1
308	Brno Registry - Drug therapy after myocardial infarction. <i>Cor Et Vasa</i> , 2009, 51, 128-130.	0.1	1
309	ACE inhibitors or sartans in the management of myocardial infarction survivors?. <i>Cor Et Vasa</i> , 2009, 51, 103-111.	0.1	1
310	Aliskiren-Hydrochlorothiazide in Combination: Efficacy Review in Mild to Moderate Hypertension. <i>Clinical Medicine Reviews in Vascular Health</i> , 0, 2, 141-149.	3.0	0
311	Evidencia actual de la combinaci3n de un IDR y un ARA II/IECA. <i>Medwave</i> , 2010, 10, .	0.5	0
314	Hyperkalemia Risk and Treatment of Heart Failure. , 2012, , 81-99.		0

#	ARTICLE	IF	CITATIONS
315	Hyperkalemia Risk and Treatment of Heart Failure. , 2012, , 23-41.		0
316	Aliskiren in Patients Failing to Achieve Blood Pressure Targets With Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. Cardiology Research, 2012, 3, 147-153.	1.1	0
317	New Therapeutics in Hypertension. , 0, , .		0
318	Comparative effects of renin-angiotensin-aldosterone system modulators on right heart function and prognosis in patients with severe systolic chronic heart failure. Cardiovascular Therapy and Prevention (Russian Federation), 2012, 11, 50-55.	1.4	1
319	New Drugs for Hypertension. , 2013, , 226-229.		0
320	Renin angiotensin aldosterone system blockade in practice: A Clinical Perspective. Ibmossina Journal of Medicine and Biomedical Sciences, 2014, 6, 57.	0.2	0
321	Almanac 2013: Heart failure the national society journals present selected research that has driven recent advances in clinical cardiology. Srce I Krvni Sudovi, 2014, 33, 273-278.	0.1	0
322	Reperfusion and Vasodilator Therapy in Elderly Patients with STEMI and Heart Failure: Improving Outcomes. , 2014, , 199-220.		0
323	Calcium Channel BlockersDirect Renin Inhibitors (DRI) as Novel Antihypertensive Agents. Journal of the Nihon University Medical Association, 2014, 73, 14-16.	0.0	0
325	How to Use Inhibitors of the Renin-Angiotensin-Aldosterone System in Patients with CKD and Heart Failure. , 2015, , 163-170.		0
326	Renal Denervation for Congestive Heart Failure. , 2015, , 163-173.		0
327	Renal dysfunction in patients with cardiovascular disease. The effects of blockers of the renin-angiotensinaldosterone system. Cardiosomatics, 2016, 7, 59-64.	0.4	0
328	THREE- AND SIX-MONTH EXPERIENCE OF EPLERENONE USE IN PATIENTS WITH ISCHEMIC DILATION CARDIOPATHY WITHOUT SIGNS OF DECOMPENSATION. Siberian Medical Review, 2017, , 103-108.	0.2	0
329	Potential effects of aliskiren on myocardial infarction on top of hypertension and heart failure in rats. Benha Medical Journal, 2018, 35, 163.	0.0	0
331	Management of Diabetic Nephropathy in the Elderly: Special Considerations. Journal of Nephrology & Therapeutics, 2012, 2, .	0.1	1
332	Managing hypertension in the elderly: a common chronic disease with increasing age. American Health and Drug Benefits, 2012, 5, 146-53.	0.5	13
333	Direct Renin Inhibitor Attenuates Left Ventricular Remodeling in Post-Myocardial Infarction Heart Failure Mice. Acta Cardiologica Sinica, 2013, 29, 160-7.	0.2	3
334	Renin-Angiotensin-Aldosterone System Activation and Diuretic Response in Ambulatory Patients With Heart Failure. Kidney Medicine, 2022, 4, 100465.	2.0	4

#	ARTICLE	IF	CITATIONS
335	Screening for High Blood Pressure at the Dentist's Office. Clinical, Cosmetic and Investigational Dentistry, 2022, Volume 14, 79-85.	1.6	1
339	Mathematical modeling of antihypertensive therapy. Frontiers in Physiology, 0, 13, .	2.8	4
340	Renin-Angiotensin-Aldosterone System as an Old New Target in Heart Failure Therapy. , 2023, , 307-330.		1